Validation of advanced hybrid SPECT/CT system using dynamic anthropomorphic cardiac phantom

Myocardial blood flow (MBF) assessment can provide incremental diagnostic and prognostic information and thus the validation of dynamic SPECT is of high importance. We recently developed a novel cardiac phantom for dynamic SPECT validation and compared its performance against the GE Discovery NM 530c. We now report its use for validation of a new hybrid SPECT/CT System featuring advanced cadmium zinc telluride (CZT) technology in a ring array detector design (StarGuide™, GE HealthCare).

Our recently developed cardiac phantom with injected technetium-99m radiotracer was used to create physiological time activity curves (TACs) for the left ventricular (LV) cavity and the myocardium. The TACs allow the calculation of uptake rate (K1) and MBF. The StarGuide system was used to acquire and process the TACs, and these were compared to the TACs produced by the phantom and its mathematical model. Fifteen (15) experiments with different doses representing various MBF values were conducted, and a standard statistic tool was applied for significance.

The TACs produced by the StarGuide system had a significant correlation (p < 0.001) with the reference TACs generated by the phantom both for the LV (r = 0.94) and for the myocardium (r = 0.89). The calculated MBF difference between the system and the phantom was 0.14 ± 0.16 ml/min/g and the average relative absolute difference was 13.2 ± 8.1%. A coefficient of variance of ≤ 11% was observed for all MBF subranges. The regional uptake rate values were similar to the global one with a maximum difference of 5%.

Our newly developed dynamic cardiac phantom was used for validation of the dynamic hybrid SPECT/CT CZT-based system (StarGuide™, GE). The accuracy and precision of the system for assessing MBF values were high. The new StarGuide system can reliably perform dynamic SPECT acquisitions over a wide range of myocardial perfusion flow rates.